Patrick K S Ng
Overview
Explore the profile of Patrick K S Ng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
228
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Saridogan T, Akcakanat A, Zhao M, Evans K, Yuca E, Scott S, et al.
Sci Rep
. 2023 Nov;
13(1):20223.
PMID: 37980453
Several alterations in fibroblast growth factor receptor (FGFR) genes have been found in breast cancer; however, they have not been well characterized as therapeutic targets. Futibatinib (TAS-120; Taiho) is a...
2.
Bagheri-Yarmand R, Busaidy N, McBeath E, Danysh B, Evans K, Moss T, et al.
Cancers (Basel)
. 2021 Oct;
13(19).
PMID: 34638434
-activating mutations are the most frequent driver mutations in papillary thyroid cancer (PTC). Targeted inhibitors such as dabrafenib have been used in advanced -mutated PTC; however, acquired resistance to the...
3.
Li X, Lau A, Ng A, Aldehaiman A, Zhou Y, Ng P, et al.
Proc Natl Acad Sci U S A
. 2021 Sep;
118(37).
PMID: 34507989
The phosphoinositide 3-kinase regulatory subunit p85α is a key regulator of kinase signaling and is frequently mutated in cancers. In the present study, we showed that in addition to weakening...
4.
Negrao M, Raymond V, Lanman R, Robichaux J, He J, Nilsson M, et al.
J Thorac Oncol
. 2020 Jun;
15(10):1611-1623.
PMID: 32540409
Introduction: Approximately 4% of NSCLC harbor BRAF mutations, and approximately 50% of these are non-V600 mutations. Treatment of tumors harboring non-V600 mutations is challenging because of functional heterogeneity and lack...
5.
Ip C, Ng P, Jeong K, Shao S, Ju Z, Leonard P, et al.
Nat Commun
. 2018 Nov;
9(1):4583.
PMID: 30389923
Activation of platelet-derived growth factor receptor alpha (PDGFRA) by genomic aberrations contributes to tumor progression in several tumor types. In this study, we characterize 16 novel PDGFRA mutations identified from...
6.
Cheung L, Yu S, Zhang D, Li J, Ng P, Panupinthu N, et al.
Cancer Cell
. 2014 Oct;
26(4):479-94.
PMID: 25284480
PIK3R1 (p85α regulatory subunit of PI3K) is frequently mutated across cancer lineages. Herein, we demonstrate that the most common recurrent PIK3R1 mutation PIK3R1(R348∗) and a nearby mutation PIK3R1(L370fs), in contrast...
7.
Activity of the MEK inhibitor selumetinib (AZD6244; ARRY-142886) in nasopharyngeal cancer cell lines
Ma B, Lui V, Cheung C, Lau C, Ho K, Hui E, et al.
Invest New Drugs
. 2012 May;
31(1):30-8.
PMID: 22565394
This study evaluated the preclinical activity of selumetinib (AZD6244, ARRY-142866), an inhibitor of the mitogen-activated protein kinase kinase (MAPKK or MEK1/2) in 6 nasopharyngeal cancer (NPC) cell lines. Selumetinib could...
8.
Law C, Leung P, Ng P, Kou C, Au K, Zhou J, et al.
J Ethnopharmacol
. 2010 Dec;
134(1):130-5.
PMID: 21130852
Aim Of The Study: Astragali radix (AR) is a widely used traditional medicine in oriental countries for treating various diseases including cardiovascular disease (CVD). We investigated the effects of AR...
9.
Lau C, Huang L, Tsui S, Ng P, Leung P, Kumta S
J Orthop Res
. 2010 Oct;
29(3):403-13.
PMID: 20886653
Giant cell tumor (GCT) is the most common nonmalignant primary bone tumor reported in Hong Kong. It usually affects young adults between the ages of 20 and 40. This tumor...
10.
Ng P, Chiu S, Kwong T, Yu R, Wong M, Kong R
BMC Mol Biol
. 2009 Nov;
10:101.
PMID: 19883516
Background: CITED proteins belong to a family of non-DNA-binding transcriptional co-regulators that are characterized by a conserved ED-rich domain at the C-terminus. This family of genes is involved in the...